{"id":"molnupiravir-esperavir","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Molnupiravir is a prodrug that is converted intracellularly to the active form, which acts as a nucleoside analog that pairs ambiguously with both purines and pyrimidines during viral RNA-dependent RNA polymerase-mediated replication. This causes a high rate of mutations in the viral genome, ultimately leading to viral inactivation through error catastrophe. The mechanism is effective against RNA viruses including SARS-CoV-2 and influenza.","oneSentence":"Molnupiravir is a nucleoside analog that induces viral mutagenesis by causing errors during viral RNA replication, leading to viral extinction.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:50:15.317Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"COVID-19 (treatment of mild to moderate disease in adults at high risk of progression)"},{"name":"Influenza (investigational)"}]},"trialDetails":[{"nctId":"NCT05595824","phase":"PHASE3","title":"Open Multicenter Study for Assessment of Efficacy and Safety of Molnupiravir in Adult Patients With COVID-19","status":"COMPLETED","sponsor":"Promomed, LLC","startDate":"2021-12-01","conditions":"COVID-19","enrollment":240}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["JCBC00101"],"phase":"phase_3","status":"active","brandName":"Molnupiravir (Esperavir)","genericName":"Molnupiravir (Esperavir)","companyName":"Promomed, LLC","companyId":"promomed-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Molnupiravir is a nucleoside analog that induces viral mutagenesis by causing errors during viral RNA replication, leading to viral extinction. Used for COVID-19 (treatment of mild to moderate disease in adults at high risk of progression), Influenza (investigational).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}